RET kinase domain fusion with kinesin family member 5B was identified in about 1–2% of patients with non-small-cell lung cancer (NSCLC), who were negative for mutations or rearrangements in other common oncogenic drivers such as EGFR, HER, ERBB2, BRAF, KRAS, ALK, etc. [110,111,112]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.